Journal of Cancer Research and Therapeutics Close
 

Figure 3: Statistically, miR-146a has higher expression level in lymph node-negative gastric tumors (normalized to U6 snRNA, **P < 0.01, as compared to lymph node-positive cases (a), and also miR-146a is expressed more in gastric tumors with Stage I (*P < 0.05, ***P < 0.001), as compared to Stages II and III (b)

Figure 3: Statistically, miR-146a has higher expression level in lymph node-negative gastric tumors (normalized to U6 snRNA, **<i>P</i> < 0.01, as compared to lymph node-positive cases (a), and also miR-146a is expressed more in gastric tumors with Stage I (*<i>P</i> < 0.05, ***<i>P</i> < 0.001), as compared to Stages II and III (b)